Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
Milan, IT, and Leiden, NL, 14 January 2020
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading, integrated toolbox of protein production and engineering technologies and screening methods using cellular, biochemical, high content and biophysical assays. These capabilities are used to probe our innovative small molecule and fragment libraries for ideally behaved hits. The hits can subsequently be evolved with our focused medicinal chemistry expertise supported by NMR and X-ray crystallography-based structural biology, all under a single, seamless contractual arrangement. The Axxam and ZoBio collaboration brings together decades of experience with unbeatable technology to help you to overcome your greatest drug discovery challenges.
Stefan Lohmer, co-founder and Chief Executive Officer of Axxam, commented, “We are very pleased to announce this strategic alliance with ZoBio. Both Axxam and ZoBio share a common philosophy based on excellence and creativity in biology. Axxam is a biology-driven company with a deep understanding of targets, assay development and high throughput screening, with a culture of scientific excellence and the attention to delivering the quality results our clients need and expect.
The complementary technical skillsets between Axxam and ZoBio provide a seamless suite of options to our clients looking to interrogate pharmacologically challenging drug targets with a variety of complementary platforms.”
Gregg Siegal, Chief Executive Officer of ZoBio added, “Fundamentally, HTS and fragments offer tremendous complementarity with the result being a far more robust drug discovery campaign. Our biophysical approach allows us to select for molecules with the desired mode of action whereas Axxam’s cellular and biochemical expertise selects molecules with the desired biological activity. While the science of our two companies is orthogonal, we share a deep commitment to excellence, which is why this is the perfect collaboration.”